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956Objective: We evaluated N-acetylcysteine, a potent antioxidant, as prevention for renal dysfunction in infants
undergoing cardiac surgery for dextro-transposition of the great arteries.
Methods: Twenty-one neonates undergoing the arterial switch operation were randomized to receive either pla-
cebo or intravenous N-acetylcysteine. Serial data were collected on fluid balance, serum creatinine, inotropic sup-
port, cardiac output, and length of stay.
Results: Hospital and 30-day survival was 100%. No serious adverse events were attributable to the drug. Sub-
jects treated with N-acetylcysteine had a higher urine output at 24 hours (175 mL vs 96 mL; P<.01) and a shorter
median time to first negative fluid balance (27 hours vs 39.5 hours; P ¼ .02). There were no differences between
groups in diuretic therapy, inotropic support, fluid intake, or chest tube output. Serum creatinine increased at 24
hours after the operation by a mean of 0.27 mg/dL with placebo (P< .01) but was unchanged with N-acetylcys-
teine treatment. By postoperative day 3, serum creatinine increased by 92% in the placebo group but only 38% in
the N-acetylcysteine group (P ¼ .04). Length of intensive care unit stay was shorter by an average of 5 days
(P ¼ .04) with N-acetylcysteine treatment.
Conclusions: In this pilot study, perioperative treatment with N-acetylcysteine resulted in improved urine output,
shorter time to negative fluid balance, and attenuation of the rise in creatinine. These effects of N-acetylcysteine
may translate to improved outcomes for infants undergoing complex cardiac operations. (J Thorac Cardiovasc
Surg 2010;139:956-61)Cardiac surgery requiring cardiopulmonary bypass (CPB) is
accompanied by varying degrees of ischemia–reperfusion
injury to multiple organs including the heart, lungs, brain,
liver, and kidneys. Multiorgan dysfunction contributes to
longer postoperative recovery times and increased morbidity
and mortality in adults and children undergoing surgical cor-
rection of major structural cardiac abnormalities.1-3 Acute
kidney injury is associated with significant morbidity and
mortality after cardiac surgery in both adults and chil-
dren.4-6 Although the precise mechanisms for renal injury
after bypass are incompletely understood, oxidant stress
has been suggested to play a major role.
N-acetylcysteine (NAC), a derivative of the naturally
occurring amino acid L-cysteine, has been used prophylac-
tically to attenuate renal injury after intravenous contraste Division of Pediatric Cardiologya and the Division of Pediatric Cardiovascu-
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The Journal of Thoracic and Cardiovascular Surgfor radiologic studies. The beneficial effect of NAC is
thought to be mediated by multiple mechanisms including
free radical scavenging, prevention of oxidative stress, lim-
itation of ischemia–reperfusion injury, and modulation of
apoptosis.7
Multiple large, randomized, placebo-controlled trials
have examined the role of NAC in the prevention of acute
kidney injury in adults, but not children, after CPB.8-12 Al-
though none of these trials showed a clear benefit of NAC
in the reduction of renal injury, two studies focusing on pa-
tients with pre-existing chronic renal insufficiency demon-
strated significant benefits of NAC in reducing the
duration of mechanical ventilation, length of intensive care
unit stay,11 and all-cause mortality.12
No previous studies have been published on the potential
renal protective effects of prophylactic NAC in infants un-
dergoing cardiac surgery. Compared with the adult kidney,
the neonatal kidney is uniquely susceptible to ischemia–re-
perfusion injury after CPB.13 In addition to the increased
susceptibility to ischemia–reperfusion injury, the clinical
outcome of infants with acute renal failure after surgery
for congenital heart disease is known to be significantly
worse, with an adjusted mortality odds ratio of 1.91 (95%
confidence interval 1.10–3.36).6
We hypothesized that prophylactic NAC would preserve
renal function after cardiac surgery in infants with complex
congenital heart disease. We chose to study the efficacy of
NAC in patients undergoing the arterial switch operationery c April 2010
Abbreviations and Acronyms
ASO ¼ arterial switch operation
CPB ¼ cardiopulmonary bypass
D-TGA ¼ dextro-transposition of the great arteries
NAC ¼ N-acetylcysteine
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D(ASO) for dextro-transposition of the great arteries (D-TGA)
because this operation is performed almost exclusively in
neonates, requires CPB, and is known to produce a predict-
able fall in cardiac output reaching a nadir between 8 and 12
hours after surgery.14 Mortality after ASO in the modern era
is quite low (<5%), but significant secondary morbidity re-
mains, including low cardiac output syndrome, postopera-
tive fluid overload, and acute renal dysfunction, with
a requirement for renal replacement therapy in 5% to 8%
of cases.15,16C
HMETHODS
This study was a randomized, placebo-controlled, double-blind trial of
intravenous NAC in neonates and infants with D-TGA and variants (includ-
ing D-TGA, ventricular septal defect, with/without aortic coarctation, and
double-outlet right ventricle, subpulmonary ventricular septal defect,
with/without aortic coarctation) undergoing ASO (with/without ventricular
septal defect closure and aortic arch repair). Exclusion criteria included pa-
tients younger than 36 weeks’ postconceptional age at the time of surgery,
patients with a birth weight less than 1800 g, and patients with clinical or
laboratory evidence of significant preoperative renal, hepatic, or neurologic
dysfunction. Informed consent was obtained from the parents or legal
guardians of all eligible patients. The study was approved by the University
of Michigan Human Subjects Institutional Review Board. Funding agencies
played no role in data interpretation.
Subjects were randomized to receive an intravenous bolus of NAC
(100 mg/kg in 5% dextrose) or placebo (5% dextrose) 1 hour before
the operation, followed by an intravenous infusion of NAC (10 mg $
kg1 $ h1) or an equal volume of placebo continuously for 24 hours after
separation from CPB. A thermodilution cardiac output catheter was posi-
tioned in the main pulmonary artery during the operation whenever tech-
nically feasible. All four surgeons who performed the ASO during the
study period standardized their intraoperative approach, including cooling
rates and temperatures, cardioplegia administration, and cannulation tech-
niques. At the conclusion of the operation, all patients underwent modi-
fied ultrafiltration.
Total fluid intake, urine output, and chest tube output were recorded
hourly per our standard cardiac intensive care unit guidelines. Blood pres-
sure, thermodilution cardiac output, central venous pressure, left atrial pres-
sure, and vasoactive inotrope score were recorded at 1, 4, 8, 12, and 24
postoperative hours. Vasoactive inotrope score was defined as follows: do-
pamine (mg $ kg1 $ min1)þdobutamine (mg $ kg1 $ min1)þ100 3 epi-
nephrine (mg $ kg1 $ min1)þ100 3 norepinephrine (mg $ kg1 $ min1)þ
10 3 milrinone (mg $ kg1 $ min1)þ10,000 3 vasopressin (units $ kg1 $
min1). Serial blood lactate levels were measured with each arterial blood
gas (typically at 2- to 4-hour intervals over the first 24-hour period). Serum
creatinine was measured preoperatively and at 1, 8, 24, 36 to 48, and 60 to
72 hours postoperatively. Postoperative mechanical ventilation time and
postoperative intensive care unit and hospital lengths of stay were recorded
(rounded to the nearest whole day). Complications and adverse events were
recorded for all subjects.The Journal of Thoracic and CaStatistical Analysis
The primary outcome measure was the change in serum creatinine from
preoperative (baseline) to 24 hours postoperative. Baseline data are repre-
sented as means with standard deviations or medians with ranges for
nonnormally distributed values. The paired t test was used to test for
within-subject changes in serumcreatinine over time. The 2-sample unpaired
t test was used to compare mean differences in fluid input/output and hemo-
dynamic parameters betweengroups. To account for the nonindependence of
the repeated measures over time, we used generalized estimating equations
to test differences in serum creatinine over time between the treatment and
placebo groups. The 2-sampleWilcoxon rank sum test was used to compare
differences in time to negative fluid balance between groups, and a Kruskal–
Wallis equality-of-populations rank test was used to compare other nonnor-
mally distributed data such as length of stay between groups.
RESULTS
Between April 2005 and June 2008, 21 patients undergo-
ing ASO were enrolled in the study. Two enrolled subjects
were removed from further analysis because a pulmonary ar-
tery band was placed before ASO in 1 placebo-treated pa-
tient and extracorporeal membrane oxygenation was
initiated before administration of the maintenance infusion
of NAC in the second. Both patients were considered proto-
col violations. Therefore, the study sample available for
analysis consisted of 9 placebo-treated and 10 NAC-treated
subjects.
Baseline demographics were similar between the 2 groups
(Table 1), and hospital as well as 30-day survival was 100%
overall.
In the placebo-treated group, serum creatinine increased
significantly compared with preoperative levels in the 24
hours after ASO (mean  standard deviation, 0.56  0.19
mg/dL vs 0.83  0.19 mg/dL; P ¼ .0016). An increase
was observed in all 9 placebo subjects at this time point.
In contrast, serum creatinine was not statistically different
between preoperative and 24-hour postoperative measure-
ments in the NAC group (0.57  0.22 mg/dL vs 0.66 
0.16 mg/dL; P ¼ .12). In 4 of 10 subjects, serum creatinine
either stayed the same or decreased at 24 hours compared
with preoperative levels (Figure 1, A). A 2-sample t test
showed a significant difference in the relative change in cre-
atinine over this period between the 2 groups (P ¼ .030).
In the placebo-treated group, serum creatinine also in-
creased significantly in the first 3 days after ASO (mean 
standard deviation, 0.56  0.19 mg/dL vs 0.99  0.44
mg/dL; P ¼ .015). In the NAC group, there was a signifi-
cantly smaller rise in serum creatinine over this time period
(0.57  0.22 mg/dL vs 0.74  0.24 mg/dL; P ¼ .012; Fig-
ure 1, B). The relative rise in serum creatinine at 3 days post-
operatively was attenuated by 60% in the NAC-treated
patients compared with the placebo group (Figure 2).
Subjects who received NAC had a 1.8-fold increase in cu-
mulative urine output over the first 24 postoperative hours
compared with the placebo group (mean  standard devia-
tion, 176  55 mL vs 96  54 mL; P ¼ .0059; Figure 3),
despite no clinically meaningful changes in either total fluidrdiovascular Surgery c Volume 139, Number 4 957
TABLE 1. Baseline characteristics of the study population
Placebo NAC P value
N 9 10 —
Mean birth weight (kg) 3.14 3.34 .33
Mean age at surgery (d) 7 6.9 .93
Mean postconceptional age at surgery (wk) 39 40 .075
Male gender (n) 4 8 .36
Balloon septostomy (n) 4 6 1.0
Noncardiac anomalies (n) 0 1 1.0
Mean serum creatinine (mg/dL) 0.56 0.57 .71
D-TGA with IVS (n) 5 7 1.0
D-TGA with ventricular septal defect (n) 2 3 1.0
DORV with subpulmonary VSD (n) 2 1 .56
Coarctation of the aorta, repair done with
DHCA (n)
4 1 .12
Intramural coronary course noted by
preoperative echocardiogram (n)
1 4 .32
CPB time (min) 184 161 .36
Crossclamp time (min) 98 85 .53
D-TGA, Dextro-transposition of the great arteries; IVS, intact ventricular septum; VSD,
ventricular septal defect; DORV, double-outlet right ventricle; CPB, cardiopulmonary
bypass.
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Dintake (669  159 mL vs 626  235 mL; P ¼ .64) or chest
tube output (135 102 mL vs 153 127 mL; P¼ .73). This
enhanced urinary response in the NAC group resulted in ear-
lier time to a negative fluid balance (defined as the first con-
secutive 6-hour period in which urine output was greater
than fluid intake) compared with the placebo-treated patients
(median, 27.0 hours vs 39.5 hours; P ¼ .022; Figure 4).Placebo
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FIGURE 1. Serum creatinine before surgery and 24 hours postoperatively (A) an
is shown for each subject at these 2 time points, with the connecting line indicatin
958 The Journal of Thoracic and Cardiovascular SurgWith the exception of a slightly higher average chlorothi-
azide dose in the placebo group at postoperative day 3, there
were no statistically significant differences in hemodynamic
parameters, cardiac output, serum lactate, inotropic support,
or diuretic therapy between the 2 study groups (Table 2).
Peritoneal dialysis was required in 2 of 9 placebo-treated
patients and in no patients in the NAC group. No subjects in
either group had end-stage renal disease. On the basis of the
Acute Kidney Injury Network criteria,17 8 of 9 patients in the
placebo group sustained acute kidney injury compared with
4 of 10 in the NAC group, with an odds ratio for acute kidney
injury after NAC treatment of 0.08 (exact 95% confidence
interval, 0.002–1.21; Fisher’s exact test P ¼ .057).
Intensive care unit length of stay was shorter by an aver-
age of 5 days in the NAC group versus the placebo group (6
vs 11 days; P ¼ .041). Although not statistically significant,
shorter average days requiring mechanical ventilator support
and hospital length of stay for the NAC group compared
with the placebo group were observed (median, 4.5 vs 7
days with ventilatory support, P¼ .12; 14 vs 16 days in hos-
pital, P ¼ .25, respectively).
No adverse events were directly attributable to NAC ad-
ministration, and no statistically significant differences
were observed between groups in the frequency of any ad-
verse event (Table 3). During the 24-hour study period, serial
cardiac output wasmeasured by thermodilution via a 4F ther-
modilution catheter inserted through a 4F femoral venous
sheath; this resulted in transient, reversible lower extremity
venous congestion in 3 subjects. Early (within 30 days)N-acetylcysteine
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FIGURE 2. Postoperative change in serum creatinine by group. Percent
change in mean serum creatinine from baseline is shown for placebo
(gray line) and N-acetylcysteine–treated (black line) subjects. Error bars
represent standard error of the mean.
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FIGURE 4. Time to negative fluid balance by group. The median time to
achieving a negative fluid balance, defined as a 6-hour period during which
urine output is greater than total fluid input, is shown for placebo andN-ace-
tylcysteine–treated patients. P is calculated from a 2-sample Wilcoxon rank
sum test. Error bars represent minimum and maximum values. *Single out-
lier at 211.2 hours.
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Dcardiac reoperation was required in 1 patient owing to resid-
ual right ventricular outflow tract obstruction. Early catheter-
based interventionwas required in 1 patient to occlude a large
aortopulmonary collateral vessel. Three of 20 subjects re-
quired early re-exploration for bleeding, with no difference
between NAC and placebo groups. Arrhythmias requiring
treatment occurred in 8 subjects, with supraventricular tachy-
cardia in 3 patients, junctional ectopic tachycardia in 4 pa-
tients, and transient complete heart block in 1 patient.
DISCUSSION
This pilot study provides preliminary evidence in support
of our hypothesis that NAC treatment is safe and attenuates
postoperative acute renal injury in neonates undergoing car-0 5 10 15 20 25 30
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FIGURE 3. Cumulative urine output over postoperative 24hours by group.
Total urine output (in milliliters) is shown for placebo (gray line) andN-ace-
tylcysteine–treated (black line) subjects. The P value is calculated from a 2-
sample unpaired t test. Error bars represent standard error of the mean.
The Journal of Thoracic and Cadiac surgery. The results were promising for NAC treatment,
whether assessed by serum creatinine, urine output, or the
Acute Kidney Injury Network consensus criteria. Compared
with placebo-treated subjects, NAC-treated subjects had, on
average, improved urine output by nearly 2-fold over the
first postoperative 24 hours, an attenuated rise in postopera-
tive serum creatinine over the first postoperative 72 hours,
and a shorter average time to a negative fluid balance. This
study was not powered to detect differences in mechanical
ventilator time, intensive care unit length of stay, or hospital
length of stay, but all 3 outcome measures were shorter for
NAC-treated patients than for placebo-treated subjects.
Serial cardiac output was measured by thermodilution be-
cause of the possibility that postoperative low cardiac out-
put, which is known to occur after ASO,14 may have been
abrogated by NAC. Previously, we showed that NAC treat-
ment of isolated, perfused rabbit kit hearts significantly at-
tenuated left ventricular dysfunction after 90 minutes of
hypothermic ischemic arrest and reperfusion (J. Charpie, un-
published data). Owing to the technical difficulties and var-
iability of thermodilution cardiac output measurements in
neonates, a much larger sample size will be required to an-
swer this important question.
NAC likely exerts its protective activity on the kidney
through at least 2 principal mechanisms, including (1) an in-
creased supply of intracellular reduced glutathione resulting
in enhanced activity of superoxide dismutase and glutathi-
one peroxidase, as well as improved oxygen-derived free
radical scavenging,18,19 and (2) inhibition of the intrinsic
pathway of apoptosis induction.20 We did not attempt to elu-
cidate the mechanism of the protective effect of NAC in this
study, and further study is warranted.
These results stand in contrast with the recent adult liter-
ature, where a large meta-analysis of 12 studies showed no
consistent benefit of NAC in attenuating renal dysfunction
in adult cardiac surgical patients.21 We believe that thisrdiovascular Surgery c Volume 139, Number 4 959
TABLE 2. Hemodynamic data, cardiac output, vasoactive inotrope
score, serum lactate, fluid balance, and diuretic requirement by group
Parameter
Placebo
(n ¼ 9)
NAC
(n ¼ 10) P value
Mean arterial pressure (mm Hg)
1 hour postop 59 56 .54
8 hours postop 49 54 .32
12 hours postop 51 53 .65
Mean cardiac index* (L $ min1 $ m2)
1 hour postop 2.5 2.6 .73
8 hours postop 2.0 2.4 .39
12 hours postop 2.2 2.8 .25
Mean VIS
1 hour postop 12.3 10.7 .43
8 hours postop 19.3 17.5 .43
12 hours postop 21.5 18.4 .18
Maximum VIS during first 24 postop
hours
23.0 20.5 .28
Mean serum lactate (mmol/L)
Maximum VIS during first 24 postop
hours
4.6 4.0 .54
Mean fluid input/output during first 24
postop hours
Total fluid input (mL) 626 669 .64
Total fluid output (mL) 249 310 .23
Chest tube output (mL) 153 135 .73
Urine output (mL) 96 175 .0059
Diuretic requirements (mg $ kg1 $ d1)
Postop day 1 furosemide 4.2 3.8 .094
Postop day 1 chlorothiazide 6.7 5.3 .74
Postop day 2 furosemide 6.3 6.2 .98
Postop day 2 chlorothiazide 20.1 17.9 .057
Postop day 3 furosemide 7.4 6.8 .75
Postop day 3 chlorothiazide 20.4 17.4
NAC, N-acetylcysteine; VIS, vasoactive inotropic score. *Data collected in a subset of
13 subjects (5 placebo and 8 NAC).
TABLE 3. Adverse events by group
Placebo
(n ¼ 9)
NAC
(n ¼ 10) P value
Bleeding, chest tube for hemothorax 0 1 1
Bleeding, early re-exploration required 2 1 .58
Early cardiac reoperation or catheter-
based intervention
2 0 .21
Arrhythmia necessitating treatment 2 6 .17
Infection necessitating treatment 4 2 .35
NAC, N-acetylcysteine.
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limited to neonates with a single, well-defined structural
congenital heart defect and no significant comorbidities. In
contrast, the adult studies included patients with multiple
cardiac abnormalities, particularly coronary artery disease,
and several coexisting risk factors for end-organ dysfunc-
tion. Second, our patients sustained a single, well-defined re-
nal insult in the context of presumably normal preoperative
renal function. Third, young age, higher risk-adjusted con-
genital heart severity (RACHS-1) score, and longer CPB
time are well-described independent risk factors for acute re-
nal failure.22 Therefore, even though they had normal kid-
neys, this is a very high risk group with a high pretest
probability of kidney injury. However, our study sample
size was small and these results require reproducibility in
larger studies across multiple centers before definitive con-
clusions can be reached.
We applied the Acute Kidney Injury Network criteria to
classify patients into groups with and without acute renal in-
jury. These criteria state that injury occurs if, within 48 hours960 The Journal of Thoracic and Cardiovascular Surgof an insult, there is an absolute increase in serum creatinine
of 0.3 mg/dL or more or by 50% over baseline, or if urine
output is below 0.5 mL $ kg1 $ h1 over a 6-hour period.17
These criteria may lead to a bias toward classification of clin-
ically significant renal injury, as exemplified by the fact that
nearly 90% of placebo-treated patients in our series met cri-
teria for acute kidney injury. Nonetheless, the application of
these criteria makes clear the impressive renoprotective ef-
fect of NAC in this population. There are multiple other clas-
sification systems for acute kidney injury, including
pediatric Risk, Injury, Failure, Loss, and End-Stage (pRI-
FLE)23,24 and the Society of Thoracic Surgeons criteria.
None of these systems has been shown to predict outcomes
in a pediatric cardiac intensive care setting.
In addition to the small sample size, our study was limited
because we did not measure glomerular filtration rate but in-
stead used changes in serum creatinine, which may overes-
timate or underestimate the true glomerular filtration rate.
By chance, 4 of the 5 patients who required aortic arch repair
were randomized to the placebo group. This could have
influenced the frequency of acute kidney injury, although
a larger study would be required to show this. In addition,
other biomarkers of renal injury that have recently been
shown to correlate with outcomes after pediatric cardiac sur-
gery, such as neutrophil gelatinase–associated lipocalin and
cystatin C, were not analyzed.25,26 Finally, NAC dosing was
extrapolated from other clinical uses such as the treatment of
acetaminophen intoxication. Given the lack of toxicity ob-
served in this study, it is possible that a higher NAC dosing
protocol could result in further renal protection.
The possibility that NAC, a seemingly safe and reason-
ably inexpensive agent, could result in significant cost sav-
ings for patients undergoing surgery for congenital heart
disease based on reduced need for renal replacement therapy
and shorter intensive care unit stays is an important finding
of this study. Definitive conclusions await a randomized,
placebo-controlled multicenter trial of NAC in neonates
and young infants undergoing surgical repair for a variety
of complex congenital heart lesions.
We acknowledge the contributions of the Michigan Congenital
Heart Outcomes Research and Discovery (M-CHORD) group, Ka-
ren King (research coordinator), and the fellows and faculty of the
Michigan Congenital Heart Center.ery c April 2010
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